Medical Device Markets

Tandem Sure Has Been Busy Lately. What’s Up with That?

MD+DI Managing Editor Omar Ford digs into the recent activity and explains what it means for Tandem and what it could mean for companies during the COVID-19 pandemic.

July 10, 2020

In the last few months, Tandem Diabetes Management has made an acquisition and signed deals with two of medtech's biggest powerhouses - Abbott Laboratories and Medtronic. But what does it all mean? MD+DI's Managing Editor Omar Ford tries to make sense of the companies recent momentum.

About the Author

Omar Ford

Omar Ford

Omar Ford is a veteran reporter in the field of medical technology and healthcare journalism. As Editor-in-Chief of MD+DI (Medical Device and Diagnostics Industry), a leading publication in the industry, Ford has established himself as an authoritative voice and a trusted source of information.

Ford, who has a bachelor's degree in print journalism from the University of South Carolina, has dedicated his career to reporting on the latest advancements and trends in the medical device and diagnostic sector.

During his tenure at MD+DI, Ford has covered a wide range of topics, including emerging medical technologies, regulatory developments, market trends, and the rise of artificial intelligence. He has interviewed influential leaders and key opinion leaders in the field, providing readers with valuable perspectives and expert analysis.

See more from Omar Ford

You May Also Like